STOCK TITAN

West Pharmaceutical (WST) CFO converts RSUs, withholds shares for taxes

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

WEST PHARMACEUTICAL SERVICES INC SVP & Chief Financial Officer Robert W. McMahon reported vesting and settlement of restricted stock units on August 11, 2026. He exercised or converted RSUs into 7,149.205 shares of common stock, and 3,109.19 shares of common stock were delivered or withheld at $351.37 per share for payment of exercise price or tax liability. The remaining common shares from these RSU conversions were retained as direct holdings. The Rule 10b5-1 trading plan checkbox was not selected.

Positive

  • None.

Negative

  • None.
Insider McMahon Robert W.
Role SVP & Chief Financial Officer
Type Security Shares Price Value
Exercise Rst. Stock Unit F1, F2 6,354.736 $0.00 $0.00
Exercise Rst. Stock Unit F1, F3 794.469 $0.00 $0.00
Exercise Common Stock F1 794.469 -- --
Exercise Price or Tax Liability Common Stock 345.515 $351.37 $121K
Exercise Common Stock F1 6,354.736 -- --
Exercise Price or Tax Liability Common Stock 2,763.675 $351.37 $971K
Holdings After Transaction: Rst. Stock Unit — 4,501.979 shares (Direct); Common Stock — 7,020.506 shares (Direct)
Footnotes (3)
  1. F1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.
  2. F2. On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date.
  3. F3. This award vests in four equal annual installments beginning on August 11, 2026.
RSU shares converted 7,149.205 shares Total underlying common stock from RSU exercises/conversions on August 11, 2026
Shares withheld for taxes/exercise 3,109.19 shares Code F deliveries/withholdings to pay exercise price or tax liability
Withholding price per share $351.37 per share Price applied to common shares delivered or withheld in Code F transactions
First RSU batch converted 6,354.736 shares Underlying common stock from one RSU transaction labeled as disposed derivative
Second RSU batch converted 794.469 shares Underlying common stock from second RSU transaction labeled as disposed derivative
Prior RSU grant size 12,670 restricted stock units Grant on August 11, 2025 with specified multi-installment vesting schedule
restricted stock unit financial
"Each restricted stock unit represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Code F financial
"Payment of exercise price or tax liability by delivering or withholding securities"
Rule 10b5-1 regulatory
"The Rule 10b5-1 trading plan checkbox was not selected"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What did WST executive Robert W. McMahon report in this Form 4?

Robert W. McMahon reported vesting and conversion of restricted stock units into common stock and related share withholding for exercise price or tax liability on August 11, 2026, reflecting routine equity compensation settlement activity.

How many restricted stock units did the WST CFO convert to common stock?

The WST CFO exercised or converted restricted stock units into 7,149.205 shares of common stock. This reflects derivative transactions in which RSUs, each representing a right to one share, were settled into directly held common shares.

How many WST shares were withheld for taxes or exercise price in this filing?

A total of 3,109.19 shares of WEST PHARMACEUTICAL SERVICES INC common stock were delivered or withheld at $351.37 per share to pay the exercise price or satisfy tax liabilities associated with the RSU settlements.

Were any of the WST CFO’s transactions under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox was not checked, and no footnote indicates a Rule 10b5-1 plan. The reported RSU conversions and share withholdings therefore are not represented as occurring under a pre-arranged trading plan.

Did the WST CFO sell any shares on the open market in this Form 4?

The reported dispositions are Code F transactions, meaning shares were delivered or withheld to pay exercise price or tax liability. The filing does not report any open-market purchase or sale transactions by the CFO.

What do the restricted stock unit footnotes indicate in the WST Form 4?

The footnotes state that each restricted stock unit equals one share of WST common stock and describe grant and vesting schedules, including prior grants of 12,670 RSUs vesting in scheduled installments and another award vesting in four annual installments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McMahon Robert W.

(Last)(First)(Middle)
530 HERMAN O. WEST DRIVE

(Street)
EXTON PENNSYLVANIA 19341

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP & Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/11/2026M794.469A(1)3,774.96D
Common Stock08/11/2026F345.515D$351.373,429.445D
Common Stock08/11/2026M6,354.736A(1)9,784.181D
Common Stock08/11/2026F2,763.675D$351.377,020.506D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Rst. Stock Unit(1)08/11/2026M6,354.736 (2) (2)Common Stock6,354.736$02,118.579D
Rst. Stock Unit(1)08/11/2026M794.469 (3) (3)Common Stock794.469$02,383.4D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.
2. On August 11, 2025, the reporting person was granted 12,670 restricted stock units, vesting in three installments - 4,223 shares (plus dividend equivalents) to vest six months from the grant date, 6,335 shares (plus dividend equivalents) to vest 12 months from the grant date and 2,112 shares (plus dividend equivalents) to vest 24 months from the grant date.
3. This award vests in four equal annual installments beginning on August 11, 2026.
Remarks:
/s/ Caitlin Hippeli, as an agent for Robert W. McMahon08/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)